1. Japan Stocks

  2. •

    Basic Materials

  3. •

    Chemicals
Nippon Kayaku Co., Ltd.

Nippon Kayaku Co., Ltd.

NPKYF
Nippon Kayaku Co., Ltd.US flagOther OTC
8.44
USD
- -
- -
1.25BMarket Cap
Nippon Kayaku Co., Ltd.
NPKYF
(Other OTC)

Recent

price

8.44

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
739.91
777.11
820.95
811.52
883.22
893.22
905.42
918.19
969.58
997.08
1,014.69
1,015.17
1,093.9
1,183.07
1,216.73
1,362.48
626.91
Revenue per Share
20.48
54.39
71.7
62.89
92.25
86.38
96.08
90.22
89.45
85.77
74.25
73.62
101.7
89.36
24.8
107.17
-11.94
Basic EPS, GAAP
44.2
73.84
58.05
56.84
65.31
25.12
26.49
95.52
41.45
61.98
62.74
63.73
80.94
42.06
43.53
-33.53
- -
Free Cash Flow per Basic Share
19.99
19.93
19.93
19.93
19.96
27.44
25.11
30.15
32.42
29.93
30.02
29.92
30.01
45.03
47.36
45.27
- -
Dividend per Share
629.12
663.88
704.56
745.29
918.34
1,030.15
1,075.55
1,120.72
1,203.22
1,247.74
1,225.71
1,332.05
1,459.05
1,532.33
1,625.18
1,673.23
1,609.26
Book Value per Share
601.48
640.31
684.32
720.61
901.86
1,015.53
1,063.23
1,107
1,182.53
1,227.57
1,206.02
1,292.02
1,413.96
1,492.89
1,602.9
1,647.89
1,584.54
Tangible Book Value per Share
182
181
181
181
181
181
180
173
173
173
173
171
169
168
166
163
166
Basic Weighted Avg Shares
134,344
141,029
148,897
147,119
160,068
161,857
162,936
159,112
167,882
172,640
175,133
173,384
184,805
198,380
201,791
222,584
103,883
Sales/Revenue/Turnover
6.97
11.34
13.99
13.19
15.05
13.78
13.33
12.35
13.47
11.55
9.98
8.76
11.39
10.84
3.64
9.17
2.47
Operating Margin (%)
10,742
10,028
9,029
9,931
10,435
10,743
11,238
11,343
11,673
11,969
12,584
13,473
14,099
14,240
14,402
14,077
- -
Depreciation Expense
3,718
9,871
13,004
11,401
16,718
15,653
17,291
15,635
15,488
14,851
12,815
12,574
17,181
14,984
4,113
17,508
-1,979
Net Income, GAAP
51.43
7.35
34.63
33.09
28.98
29.89
27.27
26.88
26.52
26.32
29.01
28.15
27.24
28.27
42
20.12
56.43
Effective Tax Rate (%)
2.77
7
8.73
7.75
10.44
9.67
10.61
9.83
9.23
8.6
7.32
7.25
9.3
7.55
2.04
7.87
-1.91
Profit Margin (%)
66,957
74,625
82,239
82,491
100,572
102,367
111,430
112,281
115,068
120,546
114,302
119,361
130,083
146,988
143,331
151,188
132,519
Working Capital
15,968
11,672
11,143
6,934
13,717
9,518
12,460
8,201
7,577
8,778
18,182
15,770
9,474
16,200
18,000
34,884
15,400
LT Debt
125,812
127,829
135,796
144,017
177,933
199,678
200,490
205,863
220,616
229,042
210,018
228,272
246,424
255,024
270,547
268,518
264,200
Total Equity
2.93
9.5
8.69
8.07
9.37
7.45
7.19
6.45
7.24
6.09
5.16
4.51
5.95
5.68
1.47
5.29
- -
Return on Invested Capital (%)
2.81
6.46
7.96
6.77
8.72
7.07
7.55
6.81
6.54
5.92
5.41
5.26
6.73
5.58
1.43
5.75
1.43
Return on Capital (%)
3.2
8.41
10.48
8.67
11.09
8.87
9.21
8.16
7.7
7
6.03
5.76
7.26
6
1.57
6.52
-0.75
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
13,450
- -
13,300
LT Borrowings
18,000
- -
15,400
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
166
166
164
Market Capitalization
- -
- -
208,560

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
203,146
- -
195,196
Cash, Cash Equivalents & STI
66,177
- -
53,786
Accounts Receivable, Net
60,267
- -
59,840
Inventories
67,008
- -
71,886
Total Current Liabilities
59,815
- -
62,677
Payables & Accruals
- -
- -
- -
ST Debt
13,450
- -
13,300
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.12%
5.09%
-0.75%
Free Cash Flow
5%
-39.16%
-175.87%
Net Income, GAAP
25.72%
55.02%
325.67%
Sales/Revenue/Turnover
3.31%
4.99%
10.3%
Total Cash Common Dividend
5.12%
8.99%
-5.86%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
48,584
49,324
51,845
52,038
201,791
2025
- -
- -
- -
- -
222,584
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16.05
- -
- -
- -
24.8
2025
- -
- -
- -
- -
107.17
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
47.36
2025
- -
- -
- -
- -
45.27
2026
- -
- -
- -
- -
- -
Similar Companies
Seya Industries Limited (SEYAIND.BO)
Resonac Holdings Corporation (4004.T)
Kazan Public Joint Stock Company Organichesky sintez (KZOS.ME)
PTT Global Chemical Public Company Limited (GCB.F)
Ganfeng Lithium Group Co., Ltd. (GNENY)
Sumitomo Chemical Company, Limited (SOMMF)
Business
Nippon Kayaku Co., Ltd. develops, manufactures and sells functional chemicals, pharmaceuticals, safety systems and agrochemicals in Japan and internationally. The company operates through Mobility and Imaging, Fine Chemicals and Life Sciences business segments; the Fine Chemicals segment supplies epoxy resins, maleimide resins, epoxy resin hardeners, reactive flame-retardant resins, acrylic esters, UV-curable resins for resists, liquid and dry film resists, LCD and semiconductor cleaners, sealants for liquid crystal displays, semiconductor manufacturing equipment including laminators, removers, mounters and UV irradiation machines, pigments for inkjet printers, dyes for inkjet textile printing, industrial inkjet inks, materials for image sensors, dichroic dyes for photochromic glass, near-infrared absorbers, dyes for textiles and paper, colorants for resins, thermal imaging colorants, pigment derivatives and catalysts for acrylic acid, acrolein and methacrylic acid production; the Mobility and Imaging segment provides airbag inflators, micro gas generators for seatbelt pretensioners, squibs, liquid crystal display parts, projector parts and x-ray analysis equipment parts; the Life Sciences segment offers anti-cancer and cancer-related drugs, biosimilars, generic drugs, interventional radiology products, cardiovascular drugs, bulk drugs and intermediates, photodynamic diagnostic agents, in vitro diagnostic medicines, intravascular embolization materials, food additives, health food ingredients, food quality preservatives, cleaning and disinfecting agents, agricultural insecticides, herbicides, fungicides, acaricides, epidemic prevention insecticides, soil fungicides and animal repellents. Nippon Kayaku also engages in real estate leasing services. Founded in 1916 and headquartered in Tokyo's Chiyoda-ku at the Meiji Yasuda Seimei Building, the company--formerly Nihon Kayaku Seizo Co., Ltd.--maintains global operations including subsidiaries like Taiwan Nippon Kayaku Co., Ltd. and overseas offices in locations such as New York, Dusseldorf and Shanghai. In August 2025, Nippon Kayaku executed a shareholders agreement with Formiica Pharmaceuticals Pte. Ltd. and CBC Co., Ltd. to establish a Singapore-based joint venture focused on in-licensing pharmaceutical products for Asia including Japan and Oceania, granting Nippon Kayaku preferential rights for Japanese development and sales to bolster its domestic pharmaceutical operations; the company also launched oncology medicine IBTROZIR Capsules 200mg in November 2025, adding to its anti-cancer portfolio.